



FOR IMMEDIATE RELEASE

Tokyo, December 25, 2019

**JT Signs Exclusive License Agreement with Salubris
for the Development and Commercialization of Enarodustat (JTZ-951)**

Japan Tobacco Inc. (JT) (TSE:2914) today announced that JT has signed an exclusive license agreement with Shenzhen Salubris Pharmaceuticals Co., Ltd. (Salubris) for the development and commercialization in Mainland China, Hong Kong, Macau and Taiwan of JT's original compound JTZ-951 (generic name: enarodustat), a hypoxia inducible factor prolyl hydroxylase (HIF-PH) inhibitor.

Enarodustat is an orally-active HIF-PH inhibitor that promotes erythropoiesis by accelerating the endogenous production of erythropoietin (EPO) and controlling the expression of molecules responsible for iron metabolism. JT filed a New Drug Application of enarodustat for anemia associated with chronic kidney disease (CKD) in Japan on November 29, 2019.

Under the terms of the agreement, Salubris will be responsible for the development and commercialization of enarodustat in Mainland China, Hong Kong, Macau and Taiwan. JT will receive an upfront payment and be eligible to receive development and commercial milestone payments as well as royalties based on market sales.

The conclusion of the agreement does not have a significant impact on the consolidated business performance of JT in the fiscal year ending December 2019.

ABOUT Anemia Associated with CKD

Anemia is one of the complications in CKD patients. The major cause of anemia in patients with CKD is thought to be a decreased ability to produce EPO in the kidney, associated with renal dysfunction. Insufficient oxygen supply due to the decreased erythrocyte counts reduces the energy production in organs and decreases mobility and activities in daily life, which leads to a poor quality of life.

ABOUT Salubris

Shenzhen Salubris Pharmaceuticals Co., Ltd. (Salubris) is a publicly traded, fully integrated pharmaceutical company [002294:CH]. Founded in 1998, Salubris has grown to achieve sales of >\$670M USD in 2018 (based on 2018 exchange rates). Salubris is headquartered in Shenzhen, China, and has over 4,000 employees working across R&D, regulatory, marketing and sales.

Salubris' marketed and pipeline products include drugs and devices in the cardiovascular, diabetes, oncology and anti-infective therapeutic areas.

More information is available at http://www.salubris.com/index_en.html

Japan Tobacco Inc. is a leading international tobacco company with operations in more than 130 countries. With over 63,000 employees, it manufactures and sells some of the world's best-known brands including Winston, Camel, MEVIUS and LD. The JT Group is committed to investing in Reduced-Risk Products (RRP) and currently markets its tobacco vapor products under the Ploom brand and various e-cigarette products under the Logic brand. The Group is also present in the pharmaceutical and processed food businesses. For more information, visit <https://www.jt.com/>.

Contact for Japan Tobacco Inc.

Masahito Shirasu, General Manager

Media and Investor Relations Division

Japan Tobacco Inc. Tokyo: +81-3-5572-4292

E-mail: jt.media.relations@jt.com